Obesity: Pathology and Therapy

  • Dean H. Lockwood
  • Thomas C. Heffner

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 149)

Table of contents

  1. Front Matter
    Pages I-XXIII
  2. Pathology

    1. Front Matter
      Pages 1-1
    2. M. DiGirolamo, J. Harp, J. Stevens
      Pages 3-28
    3. F. X. Pi-Sunyer
      Pages 29-56
    4. Y. C. Chagnon, L. Pérusse, C. Bouchard
      Pages 57-89
    5. M. D. Hirvonen, R. E. Keesey
      Pages 133-151
  3. Pharmacological and Other Treatments

    1. Front Matter
      Pages 153-153
    2. J. C. G. Halford, J. E. Blundell
      Pages 155-176
    3. L. A. Campfield, F. J. Smith
      Pages 177-194
    4. R. Konikoff, J. Dwyer
      Pages 195-236
    5. V. Drapeau, A. Tremblay
      Pages 237-258
    6. D. M. Smith, W. J. Pories, K. G. MacDonald Jr
      Pages 259-291
  4. Pharmacological Targets

    1. Front Matter
      Pages 293-293
    2. J. F. Caro, M. E. Trautmann
      Pages 295-311
    3. M. Rossi, S. R. Bloom
      Pages 313-341
    4. C. F. Burant
      Pages 369-400
  5. Strategies for Indentifying Future Targets

    1. Front Matter
      Pages 401-401

About this book

Introduction

Obesity is a serious medical problem that affects millions of people, especially in Western societies. Although long considered a complicating factor in a variety of diseases, there is now widespread agreement that obesity itself should be classified and treated as a disease and that it has important conse­ quences for personal health, quality of life and cost to society. Understanding obesity and the means of treating it have been hampered in the past. There have been misperceptions that obesity is a behavioral disorder and that its treatments provides only cosmetic benefits. Pharmacologic approaches to treatment have suffered from problems of limited efficacy, reduced activity upon chronic use, and serious side effects, including abuse liability, cardiac disease, hypertension, and respiratory complications. Finally, there has been a proliferation of consumer and natural products with unproven benefits. This book attempts to address both the problems associated with obesity and the approaches to treating it. In the first section devoted to pathology, Drs. DIGIROLAMO, HARP, and STEVENS elaborate in Chap. 1 on how obesity and its medical complications develop. As described by Dr. PI-SUNYER in Chap. 2, obesity is a disease seen most often in affluent Western societies and is associated with the aforemen­ tioned medical problems, as well as Type II diabetes mellitus and gallbladder disease. Drs. CHAGNON, PERUSSE, and BOUCHARD review the human genetics of obesity in Chap. 3, and Drs.

Keywords

CNS Fettleibigkeit Pathology diabetes diabetes mellitus insulin insulin resistance lipide metabolism neuropeptides obesity pharmacology research resistance serotonin

Editors and affiliations

  • Dean H. Lockwood
    • 1
  • Thomas C. Heffner
    • 2
  1. 1.Department of Clinical ResearchParke-Davis Pharmaceutical Research, Division of Warner Lambert CompanyAnn ArborUSA
  2. 2.Neuroscience TherapeuticsParke-Davis Pharmaceutical Research, Division of Warner Lambert CompanyAnn ArborUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-59651-3
  • Copyright Information Springer-Verlag Berlin Heidelberg 2000
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-64070-4
  • Online ISBN 978-3-642-59651-3
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • About this book
Industry Sectors
Chemical Manufacturing
Biotechnology
Consumer Packaged Goods
Pharma